Aquestive Therapeutics Stock News

WARREN, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care

First and only orally delivered epinephrine product candidate AQST-109 continues to show rapid absorption with a median time to peak concentration (Tmax) of 13.5 minutes AQST-109 was safe and well tolerated Part 2 of the EPIPHAST trial commenced WARREN, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film. Part 1 showed that key pharmacokinetic measures were aligned with previous favorable results for AQST-109 and that the product was well tolerated with no serious adverse events. A lead candidate is currently being evaluated in Part 2 of the EPIPHAST study. EPIPHAST is a randomized, open-label, three-part adaptive design, crossover study in healthy adult subjects comparing the pharmacokinetics and pharmacodynamics of epinephrine delivered via Aquestive''s AQST-109 oral film compared to intramuscular injection of epinephrine.

Aquestive Therapeutics (AQST) said the U.S. Food and Drug Administration ((FDA)) cleared its investigational new drug application ((IND)) for AQST-109 epinephrine oral film to…

WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics made several advancements last year that have set the stage for a potentially transformative year in 2022. Unfortunately, the share price ended the year on a sour note.

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Thursday, TipRanks reports. They presently have a $14.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 261.76% from the stock’s previous close. Separately, Wedbush restated a “buy” rating and set a […]

A decision on a crucial regulatory filing is being delayed indefinitely.

A decision on a crucial regulatory filing is being delayed indefinitely.

A decision on a crucial regulatory filing is being delayed indefinitely.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

The stock price of Aquestive Therapeutics, Inc. (NASDAQ: AQST) fell by over 30% pre-market today. This is why it happened.

WARREN, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address p

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.